LabCorp/$LH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About LabCorp
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
Ticker
$LH
Sector
Primary listing
NYSE
Industry
Health Care Providers & Services
Headquarters
Employees
65,450
ISIN
US5049221055
Website
LabCorp Metrics
BasicAdvanced
$21B
29.26
$8.67
0.80
$2.88
1.14%
Price and volume
Market cap
$21B
Beta
0.8
52-week high
$265.72
52-week low
$200.90
Average daily volume
692K
Dividend rate
$2.88
Financial strength
Current ratio
1.836
Quick ratio
1.281
Long term debt to equity
76.085
Total debt to equity
79.126
Dividend payout ratio (TTM)
33.20%
Interest coverage (TTM)
5.25%
Profitability
EBITDA (TTM)
1,717.3
Gross margin (TTM)
27.89%
Net profit margin (TTM)
5.55%
Operating margin (TTM)
8.66%
Effective tax rate (TTM)
21.92%
Revenue per employee (TTM)
$200,000
Management effectiveness
Return on assets (TTM)
4.18%
Return on equity (TTM)
8.98%
Valuation
Price to earnings (TTM)
29.261
Price to revenue (TTM)
1.612
Price to book
2.56
Price to tangible book (TTM)
-13.28
Price to free cash flow (TTM)
18.444
Free cash flow yield (TTM)
5.42%
Free cash flow per share (TTM)
1,375.11%
Dividend yield (TTM)
1.14%
Forward dividend yield
1.14%
Growth
Revenue change (TTM)
7.13%
Earnings per share change (TTM)
73.29%
3-year revenue growth (CAGR)
-4.45%
10-year revenue growth (CAGR)
7.57%
3-year earnings per share growth (CAGR)
-26.46%
10-year earnings per share growth (CAGR)
6.68%
What the Analysts think about LabCorp
Analyst ratings (Buy, Hold, Sell) for LabCorp stock.
Bulls say / Bears say
Labcorp's core diagnostics business is experiencing healthy volume growth, with Jefferies raising the price target to $265, reflecting confidence in the company's performance. (Investing.com)
The company has expanded its oncology offerings with advanced tests like Plasma Detect, enhancing its position in high-growth areas. (Finviz)
Labcorp's strategic acquisitions, including select assets from Invitae, are expected to drive top-line growth of approximately 10% and be slightly accretive to earnings in 2025. (Finviz)
Labcorp faced a class action lawsuit in 2024 for allegedly sharing confidential patient information with Google, potentially impacting its reputation. (Wikipedia)
Employees have criticized the company's productivity goals, claiming that volume and speed are prioritized over quality, which could affect service standards. (Wikipedia)
Labcorp has been criticized over faulty paternity tests, many of which have resulted in lawsuits, potentially affecting its credibility. (Wikipedia)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
LabCorp Financial Performance
Revenues and expenses
LabCorp Earnings Performance
Company profitability
LabCorp News
AllArticlesVideos
ASU, Labcorp, and InStride announce first-of-its-kind diagnostics industry partnership that tackles critical healthcare workforce shortage
GlobeNewsWire·1 month ago
Genetic Screening Testing for the Preventive Health Market, 2025-2035 Analysis - Dominated by Exact Science, Labcorp Genetics, Blueprint Genetics, Ambry Genetics, and Genex Diagnostics
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Aug28
LabCorp
Dividend·Ex-dividend
Sept11
LabCorp
Dividend·Payment
$0.72Per share
FAQs
What’s the current market cap for LabCorp stock?
LabCorp (LH) has a market cap of $21B as of July 11, 2025.
What is the P/E ratio for LabCorp stock?
The price to earnings (P/E) ratio for LabCorp (LH) stock is 29.26 as of July 11, 2025.
Does LabCorp stock pay dividends?
Yes, the LabCorp (LH) stock pays dividends to shareholders. As of July 11, 2025, the dividend rate is $2.88 and the yield is 1.14%. LabCorp has a payout ratio of 33.2% on a trailing twelve-month basis.
When is the next LabCorp dividend payment date?
The next LabCorp (LH) dividend payment is scheduled for September 11, 2025.
What is the beta indicator for LabCorp?
LabCorp (LH) has a beta rating of 0.8. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.